Q4 2025 Ironwood Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Ironwood Pharmaceuticals Inc (IRWD) achieved $865 million in LINZESS US net sales for 2025, supported by an 11% demand growth and 8% new to brand volume growth year over year.
- LINZESS received FDA approval for treating irritable bowel syndrome with constipation in patients aged 7 and older, expanding its clinical utility.
- The company plans to lower the LINZESS list price effective January 1, 2026, to support ongoing patient access.
- Ironwood Pharmaceuticals Inc (IRWD) ended 2025 with $250 million in cash and cash equivalents, positioning the company well for 2026.
- The company expects LINZESS to return to blockbuster status in 2026 with over $1.1 billion in US net sales, driven by improved net price and low single-digit prescription demand growth.
- Fourth quarter LINZESS US net sales decreased 27% year over year due to net price erosion.
- Full year LINZESS US net sales decreased 6% year over year, primarily due to Medicare Part D redesign.
- The company faces potential competitive pressure in the short bowel syndrome market with the presence of other GLP-2 therapies.
- Ironwood Pharmaceuticals Inc (IRWD) anticipates the need for a confirmatory phase 3 trial for apraglutide, which may delay its market entry.
- There is ongoing volatility in LINZESS pricing due to timing of recognition of gross to net rebate reserves.
Thank you for standing by. My name is Liz, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Ironwood Pharmaceuticals Q4 and full year 2025 Investor Update conference call. All lines have been placed on mute to prevent any background noise (Operator Instructions). Thank you. I would now like to turn the call over to Greg Martini, Chief Financial Officer. Please go ahead.
Good morning and thank you for joining us for our fourth quarter and full year 2025 Investor Update. A press release issued this morning can be found on our website.
Today's call and accompanying slides include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially.
A discussion of these statements and risk factors is available on the current Safe Harbor statement slide, as well as under the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
